Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gal Markel

Showing results (81-90 of 137) with videos related to

Pageof 14
Sort By:
Cancer Immunology, Immunotherapy : CII|November 17, 2020
microRNA expression patterns in tumor infiltrating lymphocytes are strongly associated with response to adoptive cell transfer therapyGilli Galore-Haskel, Eyal Greenberg, Inbal Yahav, et al.
Oncoimmunology|December 21, 2020
MIF inhibition as a strategy for overcoming resistance to immune checkpoint blockade therapy in melanomaRicardo A de Azevedo, Einav Shoshan, Shanzhi Whang, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 22, 2004
MHC class I-independent recognition of NK-activating receptor KIR2DS4Gil Katz, Roi Gazit, Tal I Arnon, et al.
The Oncologist|March 12, 2026
PD-1 inhibitor treatment outcomes for cutaneous squamous cell carcinoma in patients over 85: a comparative analysisIdo Amir, Nofar Edri, Itamar Averbuch, et al.
Plos One|May 15, 2009
Natural killer lysis receptor (NKLR)/NKLR-ligand matching as a novel approach for enhancing anti-tumor activity of allogeneic NK cellsGal Markel, Rachel Seidman, Michal J Besser, et al.
JAMA Network Open|March 9, 2022
Comparison of 3 Randomized Clinical Trials of Frontline Therapies for Malignant Pleural MesotheliomaTomer Meirson, Francesca Pentimalli, Francesco Cerza, et al.
Experimental and Therapeutic Medicine|September 13, 2012
Adoptive cell therapy with autologous tumor-infiltrating lymphocytes and high-dose interleukin-2 for metastatic melanoma: The surgeon's perspectiveDouglas B Zippel, Michal Besser, Roni Shapira, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 9, 2002
CD66a interactions between human melanoma and NK cells: a novel class I MHC-independent inhibitory mechanism of cytotoxicityGal Markel, Niva Lieberman, Gil Katz, et al.
JAMA Network Open|January 22, 2025
Reanalysis of Urothelial Cancer Chemoimmunotherapy Trials With Differential CensoringTomer Meirson, Jonathan Ofer, Noa Zimhony-Nissim, et al.
Journal of Translational Medicine|December 13, 2022
Analysis of new treatments proposed for malignant pleural mesothelioma raises concerns about the conduction of clinical trials in oncologyTomer Meirson, Valerio Nardone, Francesca Pentimalli, et al.
Pageof 14

Showing results (81-90 of 137) with videos related to

Sort By:
Pageof 14
Cancer Immunology, Immunotherapy : CII|November 17, 2020
microRNA expression patterns in tumor infiltrating lymphocytes are strongly associated with response to adoptive cell transfer therapyGilli Galore-Haskel, Eyal Greenberg, Inbal Yahav, et al.
Oncoimmunology|December 21, 2020
MIF inhibition as a strategy for overcoming resistance to immune checkpoint blockade therapy in melanomaRicardo A de Azevedo, Einav Shoshan, Shanzhi Whang, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 22, 2004
MHC class I-independent recognition of NK-activating receptor KIR2DS4Gil Katz, Roi Gazit, Tal I Arnon, et al.
The Oncologist|March 12, 2026
PD-1 inhibitor treatment outcomes for cutaneous squamous cell carcinoma in patients over 85: a comparative analysisIdo Amir, Nofar Edri, Itamar Averbuch, et al.
Plos One|May 15, 2009
Natural killer lysis receptor (NKLR)/NKLR-ligand matching as a novel approach for enhancing anti-tumor activity of allogeneic NK cellsGal Markel, Rachel Seidman, Michal J Besser, et al.
JAMA Network Open|March 9, 2022
Comparison of 3 Randomized Clinical Trials of Frontline Therapies for Malignant Pleural MesotheliomaTomer Meirson, Francesca Pentimalli, Francesco Cerza, et al.
Experimental and Therapeutic Medicine|September 13, 2012
Adoptive cell therapy with autologous tumor-infiltrating lymphocytes and high-dose interleukin-2 for metastatic melanoma: The surgeon's perspectiveDouglas B Zippel, Michal Besser, Roni Shapira, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 9, 2002
CD66a interactions between human melanoma and NK cells: a novel class I MHC-independent inhibitory mechanism of cytotoxicityGal Markel, Niva Lieberman, Gil Katz, et al.
JAMA Network Open|January 22, 2025
Reanalysis of Urothelial Cancer Chemoimmunotherapy Trials With Differential CensoringTomer Meirson, Jonathan Ofer, Noa Zimhony-Nissim, et al.
Journal of Translational Medicine|December 13, 2022
Analysis of new treatments proposed for malignant pleural mesothelioma raises concerns about the conduction of clinical trials in oncologyTomer Meirson, Valerio Nardone, Francesca Pentimalli, et al.
Pageof 14